| Dec 25 | |
|---|---|
| Income Statement | |
| Total Revenue | $ 0.00 |
| Gross Profit | $ 0.00 |
| Operating Income | $ -70.12M |
| EBITDA | $ -69.81M |
| Net Income | $ -63.91M |
| Balance Sheet | |
| Cash & Short-Term Investments | $ 185.49M |
| Total Assets | $ 194.78M |
| Total Debt | $ 1.22M |
| Net Debt | $ -86.75M |
| Total Liabilities | $ 371.42M |
| Stockholders' Equity | $ -176.63M |
| Cash Flow | |
| Free Cash Flow | $ -61.49M |
| Operating Cash Flow | $ -61.48M |
| Investing Cash Flow | $ -81.48M |
| Financing Cash Flow | $ 156.30M |
Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ:COAG
